Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma DOI Creative Commons
Amal Babu,

Padmanaban Sathiyamoorthy,

Sahil Chahal

и другие.

Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)

Опубликована: Дек. 19, 2024

The substantial mortality and morbidity of hepatocellular carcinoma, representing 90% liver cancers, poses a significant health burden. effectiveness traditional carcinoma treatments such as surgical resection, radiotherapy, chemotherapy is limited, underscoring the need for innovative therapeutic strategies. To this end, we synthesized phthalyl-pullulan nanoparticles encapsulating IR780 (an NIR-responsive heptamethine cyanine dye) R848 (resiquimod; TLR7/8 agonist) (PIR NPs). Characterization confirmed size loading capacity PIR NPs, controlled release therefrom upon NIR irradiation, thereby establishing potential versatile tool. NPs were readily taken up by Hepa 1-6 cells in vitro targeting asialoglycoprotein receptors present on its cellular surface. In vivo experiments combining photothermal therapy immunotherapy, following local near-infrared accumulated tumor sites induced immunogenic cell death activated tumor-specific T-cell immune response, thus highlighting their potent antitumor efficacy. combined efficacy immunotherapy presents promising avenue addressing shortcomings interventions. This study contributes valuable insights into development more effective targeted approaches treatment.

Язык: Английский

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis DOI

Baofa Yu,

Wenxue Ma

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 79, С. 29 - 38

Опубликована: Авг. 24, 2024

Язык: Английский

Процитировано

9
c-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma DOI

Yasamin Haghir-Sharif-Zamini,

Arezoo Khosravi, Moustapha Hassan

и другие.

Archives of Biochemistry and Biophysics, Год журнала: 2025, Номер unknown, С. 110306 - 110306

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment DOI Creative Commons

Jiarui Lv,

Yanan Wang,

Jiacheng Lv

и другие.

Cell Death and Disease, Год журнала: 2025, Номер 16(1)

Опубликована: Янв. 26, 2025

Язык: Английский

Процитировано

0
Dihydroartemisinin suppresses COX-2-mediated apoptosis resistance in hepatocellular carcinoma under endoplasmic reticulum stress DOI
Lulu Cao, Jun Lin, Yun Fang

и другие.

Cytotechnology, Год журнала: 2025, Номер 77(2)

Опубликована: Фев. 13, 2025

Язык: Английский

Процитировано

0
QSAR-Based Drug Repurposing and RNA-Seq Metabolic Networks Highlight Treatment Opportunities for Hepatocellular Carcinoma Through Pyrimidine Starvation DOI Open Access

Nicholas Dale D. Talubo,

Estela Máris Amorim Cruz,

Peter Matthew Paul Fowler

и другие.

Cancers, Год журнала: 2025, Номер 17(5), С. 903 - 903

Опубликована: Март 6, 2025

Background/Objectives: The molecular heterogeneity and metabolic flexibility of Hepatocellular Carcinoma (HCC) pose significant challenges to the efficacy systemic therapy for advanced cases. Early screening difficulties often delay diagnosis, leading more stages at presentation. Combined with inconsistent responses current therapies, HCC continues have one highest mortality rates among cancers. Thus, this paper seeks contribute development options through consideration HCC's vulnerabilities lay groundwork future in vitro studies. Methods: Transcriptomic data were used calculate single double knockout using genetic Minimal Cut Sets. Furthermore, QSAR modeling, drug repositioning opportunities assessed inhibit selected genes. Results: Two that also annotated as essential pairs found within pyrimidine metabolism pathway HCC, wherein either DHODH or TYMS is potentially disruptive proliferation. result flux balance analysis gene simulation indicated a decrease biomass production. Three machine learning algorithms their performance predicting pIC50 given compound SVM-rbf performed best on unseen achieving an R2 0.82 0.81 TYMS. For DHODH, drugs Oteseconazole, Tipranavir, Lusutrombopag identified potential inhibitors. TYMS, Tadalafil, Dabigatran, Baloxavir Marboxil, Candesartan Cilexetil showed promise Conclusions: Overall, study suggests testing assess capabilities inducing starvation HCC.

Язык: Английский

Процитировано

0
Liver cancer: Current and new drug delivery systems DOI
Samson A. Adeyemi, Lindokuhle M. Ngema, Yahya E. Choonara

и другие.

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 1 - 13

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma DOI Open Access

Toru Ishikawa,

Ryo Sato, Ryo Jimbo

и другие.

In Vivo, Год журнала: 2024, Номер 38(5), С. 2501 - 2505

Опубликована: Янв. 1, 2024

The prognosis of hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombus (PVTT) is extremely poor. This study investigated whether local ablation-a curative treatment similar to resection-could improve the patients Child-Pugh B/C PVTT.

Язык: Английский

Процитировано

1
Machine learning-based ultrasomics for predicting response to tyrosine kinase inhibitor in combination with anti-PD-1 antibody immunotherapy in hepatocellular carcinoma: a two-center study DOI Creative Commons
Yiwen Hu, Linlin Zhang, Qinghua Qi

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Ноя. 14, 2024

Objective The objective of this study is to build and verify the performance machine learning-based ultrasomics in predicting response combination therapy involving a tyrosine kinase inhibitor (TKI) anti-PD-1 antibody for individuals with unresectable hepatocellular carcinoma (HCC). Radiomic features can reflect internal heterogeneity tumor changes its microenvironment. These are closely related pathological observed histology, such as cellular necrosis fibrosis, providing crucial non-invasive biomarkers predict patient treatment prognosis. Methods Clinical, pathological, pre-treatment ultrasound image data 134 patients recurrent or advanced HCC who treated TKI at Henan Provincial People’s Hospital First Affiliated Zhengzhou University between December 2019 November 2023 were collected retrospectively analyzed. Using stratified random sampling, from two hospitals assigned training cohort ( n = 93) validation 41) 7:3 ratio. After preprocessing images, regions interest (ROIs) delineated. Ultrasomic extracted images dimensionality reduction feature selection. By utilizing extreme gradient boosting (XGBoost) algorithm, three models developed: clinical model, an ultrasomic combined model. analyzing area under receiver operating characteristic (ROC) curve (AUC), specificity, sensitivity, accuracy, predicted was evaluated. In addition, we identified optimal cutoff radiomic score using Youden index applied it stratify patients. Kaplan-Meier (KM) survival curves used examine differences progression-free (PFS) groups. Results Twenty selected construction AUC model 0.999 (95%CI: 0.997-1.000) 0.828 0.690-0.966), which compared significant favorably those [AUC 0.876 0.815-0.936) cohort, 0.766 0.597-0.935) cohort]. Compared demonstrated comparable within (AUC 0.977, 95%CI: 0.957-0.998) but higher 0.881, 0.758-1.000). However, there no statistically difference p > 0.05). Furthermore, associated PFS, significantly different scores (Rad-score) greater than 0.057 Rad-score less both (HR 0.488, 95% CI: 0.299-0.796, 0.003) cohorts 0.451, 0.229-0.887, 0.02). Conclusion demonstrates excellent accurately immunotherapy among HCC.

Язык: Английский

Процитировано

1
Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment DOI

Sumit Roy,

Vancha Harish, Sharfuddin Mohd

и другие.

Advanced Therapeutics, Год журнала: 2024, Номер unknown

Опубликована: Июль 6, 2024

Abstract Hepatocellular carcinoma (HCC) is a progressed form of advanced liver cancer and one the major causes global burden. The primary for high HCC mortality delayed diagnosis diseaseas early stage typically asymptomatic patients frequently overlook warning signs. Currently, most efficacious single‐drug therapy approved by food drug administration (FDA) Sorafenib Nivolumab as second‐line late HCC. Nowadays nanotechnology used to deliver either diagnostic tool biomolecular imaging ortherapeutic agent. Gene based on clustered regularly interspaced short palindromic repeats (CRISPR)‐CRISPR associated protein 9 (CRISPR‐Cas9) are currently studied find potential curative option Natural products from plants being extensively extracted isolated they may offer promising alternative in order control treat They exhibit anti‐HCC effects stimulating immune system hindering various growth pathways involved development progression. In this review article, an overview provided current incidence, ongoing systemic treatment strategies, recent advances nanomedicine management also efforts overcome these challenges.

Язык: Английский

Процитировано

0
Identification of Hub Genes and CDK1-Targeting Therapeutics in Hepatocellular Carcinoma: Bioinformatics and Simulation Study DOI Creative Commons
R. Romero, Cláudio Fabiano Motta Toledo

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Окт. 14, 2024

Abstract Background Hepatocellular carcinoma (HCC) remains a significant global health challenge, often associated with chronic hepatitis B (HBV) and C (HCV) infections. Novel therapeutic approaches are urgently needed to improve patient outcomes. Objective To identify validate potential targets novel drug candidates for HBV, HCV, HCC using integrative bioinformatics molecular dynamics simulations. Methods Gene expression datasets from studies were analyzed dysregulated genes. Protein-protein interaction networks constructed determine hub Virtual screening of kinase compound libraries against CDK1 was performed, followed by docking Drug-likeness metabolic properties hit compounds evaluated. Results Seven genes identified, including five upregulated (CDK1, AURKB, CCNA2, BUB1B, RRM2) two downregulated (AGXT2, ESR1) yielded three promising (G213-0272, E130-0174, Z666960592) targeting CDK1. E130-0174 demonstrated the most favorable profile, stable binding no inhibition major cytochrome P450 enzymes. Two repurposed drugs, alvocidib riviciclib, also showed as inhibitors. Conclusions This study identified inhibitors profiles treatment. The approach combining simulations provides robust framework identifying in related liver diseases. Further experimental validation is warranted confirm these findings advance development new treatments.

Язык: Английский

Процитировано

0